News
ACIU
3.910
0.00%
0.000
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Seeking Alpha · 10h ago
AC Immune stock climbs 7% on FDA fast track status for Alzheimer's drug
AC Immune stock climbs 7% on FDA fast track status for Alzheimer's drug for the treatment of Alzheimer's disease. The drug is being developed by partner Johnson & Johnson's Janssen unit. The FDA has granted Fast Track designation to AC Immune's drug candidate.
Seeking Alpha · 1d ago
AC Immune’s Alzheimer’s Drug Fast-Tracked by FDA
TipRanks · 1d ago
BRIEF-Ac Immune’S Aci-35.030 (Now “JNJ-2056”) Granted FDA Fast Track Designation For Alzheimer’S Disease
Reuters · 1d ago
Weekly Report: what happened at ACIU last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at ACIU last week (0708-0712)?
Weekly Report · 07/15 11:37
Weekly Report: what happened at ACIU last week (0701-0705)?
Weekly Report · 07/08 11:39
Weekly Report: what happened at ACIU last week (0624-0628)?
Weekly Report · 07/01 11:40
Weekly Report: what happened at ACIU last week (0617-0621)?
Weekly Report · 06/24 11:49
Swiss stocks - Factors to watch on June 21
Swiss National Bank cut interest rates on Thursday for the second time running. Swiss May Money Supply M3 due at 0700 GMT. Annual general meeting of AC IMMUNE SA to be held on Friday. The Swiss National Bank is expected to announce a cut in interest rates.
Reuters · 06/21 04:56
AC Immune SA Announces Major Takeda Partnership
TipRanks · 06/20 20:57
Weekly Report: what happened at ACIU last week (0610-0614)?
Weekly Report · 06/17 11:38
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
NASDAQ · 06/14 15:10
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Shares of RH (NYSE:RH) fell sharply in today's pre-market trading after the company reported mixed first-quarter financial results. RH shares dipped 11.6% to $244.97 in pre- market trading. The Dow futures fell 250 points on Friday.
Benzinga · 06/14 09:50
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
NASDAQ · 06/13 10:09
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
NASDAQ · 06/12 14:22
Analysts Are Bullish on Top Healthcare Stocks: AC Immune SA (ACIU), MoonLake Immunotherapeutics (MLTX)
TipRanks · 06/11 01:11
Weekly Report: what happened at ACIU last week (0603-0607)?
Weekly Report · 06/10 11:41
Weekly Report: what happened at ACIU last week (0527-0531)?
Weekly Report · 06/03 11:44
BTIG Initiates Coverage of AC Immune (ACIU) with Buy Recommendation
NASDAQ · 05/31 22:29
More
Webull provides a variety of real-time ACIU stock news. You can receive the latest news about AC Immune through multiple platforms. This information may help you make smarter investment decisions.
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.